Insulin oral - Oramed Pharmaceuticals

Drug Profile

Insulin oral - Oramed Pharmaceuticals

Alternative Names: Orally ingestible insulin capsule - Oramed Pharmaceuticals; ORMD-0801

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oramed Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 05 Sep 2017 Oramed plans a three-month clinical trial in Type 2 diabetes
  • 30 Apr 2017 Oramed and The University of Texas Health Science Center at San Antonio complete a phase II trial in Type-1 diabetes mellitus in USA (NCT02535715)
  • 01 Nov 2016 Oramed and Integrium plan a phase IIa trial for Type-2 diabetes mellitus in USA (PO) (NCT02954601)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top